Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
May 08, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
Auvelity® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million, including Sunosi® ex-U.S. license agreement upfront...
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
May 03, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
May 01, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting
April 21, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 14, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 14, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8
April 13, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
March 01, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 27, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
Total fourth quarter net product sales of $24.4 million Auvelity® launched October 19th, with fourth quarter net product sales of $5.2 million Sunosi® fourth quarter net product sales of $19.2...
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
February 22, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to receive an upfront payment of $66 million, and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future...
Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 07, 2023 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...